However, the development of trastuzumab and the subsequent clinical trials which have tested newer HER2-targeted therapies (including lapatinib and pertuzumab) in combination with trastuzumab, have significantly improved the outcomes of women with early-stage HER2-positive breast cancer [1]. Here, ERBB2 is linked to breast carcinoma.